Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

Benign or Malignant? No Way to Tell Radiologically

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

More Evidence Ties Microplastics to Lung Cancer

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

9/11's Latest Wave of Cancers, 25 Years On

Study Warns on Venetoclax in Double-Hit Lymphoma

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Recommended News For You

Stem Cell Transplant Associated With Better PFS in NKTCL

In inflammatory breast cancer, ER beta regulates estrogen signaling.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Risk of a second cancer after early breast cancer is low, say new findings

Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

Recommended Articles For You

The Rise of Immunotherapy: New Advances in Cancer Treatment

Unmasking the Subtle Symptoms of Colon Cancer

Finding Support: Connecting with the Vitiligo Community

Guidance for Managing Complex Anticoagulation

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.